GSK gets US FDA approval for expanded use of RSV vaccine

Core Viewpoint - GSK has received FDA approval to expand the age range for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk of lower respiratory tract disease, enhancing its market potential [1]. Company Summary - GSK's Arexvy is already approved for adults aged 60 and above, as well as at-risk adults aged 50 to 59 [1]. - The vaccine targets a significant population, with an estimated 21 million adults under 50 in the U.S. having at least one risk factor for severe RSV infection [1]. - Arexvy will compete with Moderna's mRESVIA and Pfizer's Abrysvo in the 18-49 age group [1]. Industry Summary - RSV is a common respiratory virus that leads to seasonal infections and is a major cause of pneumonia and death in infants and older adults [1]. - The European Medicines Agency has also supported the use of Arexvy for all adults above the age of 18, indicating a broader acceptance and potential market expansion in Europe [1].